AgomAb Therapeutics NV (NASDAQ:AGMB)
| Market Cap | $268.40M-62.8% |
| Revenue (ttm) | $0 |
| Net Income | -$35.68M |
| EPS | -$0.79 |
| Shares Out | 49.25M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 188,938 |
| Open | $5.51 |
| Previous Close | $5.62 |
| Day's Range | $5.42 - $5.78 |
| 52-Week Range | $5.39 - $17.82 |
| Beta | 1.80 |
| Analysts | n/a |
| Price Target | $35.00(+542.20%) |
| Earnings Date | Mar 3, 2027 |
About AGMB
AgomAb Therapeutics N.V. is a clinical-stage biopharmaceutical company dedicated to developing novel, disease-modifying therapies. Its primary focus lies in immunology and inflammatory ailments, particularly chronic fibrotic conditions where significant unmet medical needs persist. Its innovative pipeline features several promising candidates, including Ontunisertib (AGMB-129), an orally administered, gastrointestinal-restricted small molecule inhibitor targeting ALK5 or TGFßR1, designed to treat Fibrostenosing Crohn's disease and presently undergoing Phase 2a clinical trials. Also in development is AGMB-447, an inhaled small molecule that similarly inhibits ALK5 or TGFßR1, intended for idiopathic pulmonary fibrosis and currently in Phase 1 clinical studies. Furthermore, the company is advancing AGMB-101, a monoclonal antibody designed to mimic HGF. This agent exerts its effects through the agonism or stimulation of the MET receptor, having demonstrated both antifibrotic and regenerative capabilities in preclinical models. Established in 2017, AgomAb Therapeutics maintains its headquarters in Antwerp, Belgium.
AgomAb Therapeutics NV Stock Analysis — InsiderScore
AgomAb Therapeutics NV scored higher than 51% of companies evaluated by InsiderBuying, and ranked 37th out of 110 stocks in the biotech sector.
Scores are percentile-ranked against every company we scored that day, with extra weight given to the size and conviction of each purchase and the seniority of the buyer.
Insiders at AgomAb Therapeutics NV bought $620.0K of stock across 18 purchases in the last 90 days, the largest of them $50.9K.
The average purchase added about 24% to the buyer's existing holding. Doubling a stake earns full marks here; topping up an already large position earns very little.
2 of these purchases were made by someone who held no stock at all beforehand — going from nothing to a position is the strongest form of this signal.
This category carries 35% of the Insider Score.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
When insiders bought and sold
1 year · open-market trades onlyNext catalysts
- Mar 3, 2027Earnings report
$AGMB stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in AGMB holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by AGMB's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
AGMB Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New AGMB patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to AGMB from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in AGMB
| SBIOALPS Medical Breakthroughs ETF | $326.06K |
Estimated from each fund’s disclosed top holdings × AUM
Bull Case vs Bear Case
AI-generated from AGMB’s recent data — informational, not investment advice
What’s Behind the Score
Recent Insider Activity
Insider Score Trend Over Time
-30.0 since Oct 7Composite Insider Score (0–100) recomputed on each scoring run from live SEC Form 4 data.
Frequently Asked Questions
ETFs that hold this stock
| SBIO | ALPS Medical Breakthroughs ETF | 0.20% |
Weight is the stock’s share of each fund’s holdings.
